Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7033877 (Murepavadin) QT/QTc Study in Healthy Volunteers
NCT02165332Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Nov 2014
- Modality
- Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of murepavadin in Pseudomonas aeruginosa infection (6 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events up to 30 days, Area under the curve at Day 1 and 1 more. Started Jul 2014; status: completed.
02
Drugs
murepavadin
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02165332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02165332.